Lartruvo-soft tissue sarcoma drug to sell in U.S.

November 4, 2016 Off By Dino Mustafić

FDA granted accelerated approval to Lartruvo (olaratumab) injection, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.

The approved recommended dosage of Lartruvo is 15 mg/kg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. For the first 8 cycles, Lartruvo is administered with doxorubicin. Refer to doxorubicin prescribing information for dosing and dose modifications